Categories
Prostate cancer

PRESTO: ADT Intensification Prolongs PSA PFS in Biochemically Recurrent Prostate Cancer

Adding apalutamide to androgen deprivation therapy (ADT) prolongs prostate-specific antigen (PSA) progression-free survival (PFS) in patients with biochemically recurrent prostate cancer, according to results from the phase 3 PRESTO trial.

The results also suggest that adding abiraterone acetate, prednisone, and apalutamide to ADT prolongs PSA PFS. However, it isn’t clear if this 4-drug combination provides an additional benefit over the 2-drug combination, as the trial was not powered to compare these 2 interventions.

These findings were presented at ESMO Congress 2022 by Rahul Aggarwal, MD, of the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center.


Continue Reading

The PRESTO study (ClinicalTrials.gov Identifier: NCT03009981) enrolled 503 patients who had undergone radical prostatectomy and had biochemical recurrence with PSA levels greater than 0.5 ng/mL and a doubling time of 9 months or less. Patients had no metastases on conventional imaging, and their last dose of ADT was more than 9 months prior to study entry.

At baseline, the patients had a median age of 66.7 years, and 83.7% were White. The median PSA level was 1.77 ng/mL, and 74.2% of patients had a PSA doubling time of 3-9 months.

The patients were randomly assigned to receive 1 of the following treatments for 52 weeks or until disease progression:

  • Luteinizing hormone-releasing hormone (LHRH) analog monotherapy (n=166)
  • LHRH analog plus apalutamide (n=168)
  • LHRH analog, apalutamide, abiraterone acetate, and prednisone (n=169).

Results showed that apalutamide improved PSA PFS. At a median follow-up of 21.5 months, the median PSA PFS was 20.3 months in the ADT monotherapy arm and 24.9 months in the apalutamide-ADT arm (hazard ratio [HR], 0.52; 95% CI, 0.35-0.77; P =.00047).

Likewise, adding apalutamide, abiraterone acetate, and prednisone to ADT prolonged PSA PFS. At a median follow-up of 21.3 months, the median PSA PFS was 20.0 months in the ADT monotherapy arm and 26.0 months in the 4-drug arm (HR, 0.48; 95% CI, 0.32-0.71; P =.00008).

A subgroup analysis showed a benefit with both experimental arms in patients with a PSA doubling time less than 3 months and in those with a PSA doubling time of 3-9 months.

In the testosterone-evaluable population, prolonged PSA PFS was observed in the apalutamide-ADT arm (HR, 0.53; 95% CI, 0.34-0.82; P =.00197) and the 4-drug arm (HR, 0.60; 95% CI, 0.39-0.92; P =.00851) compared with the ADT-alone arm. There were no significant differences between the arms in time to testosterone recovery (>50 ng/dL).

Adverse events (AEs) occurred in 90.6% of patients in the monotherapy arm, 90.8% in the 2-drug arm, and 96.3% in the 4-drug arm. Grade 3-4 AEs occurred in 18.8%, 25.2%, and 37.9%, respectively.

The most common grade 3 or higher AE was hypertension, which occurred in 8% of the monotherapy recipients, 7% of the dual therapy recipients, and 19% of patients who received the 4-drug combination.

Follow-up for this trial is ongoing, and the researchers aim to determine the impact of ADT plus androgen receptor pathway inhibition on patient-reported outcomes, time to castration resistance, and metastasis-free survival.

However, Dr Aggarwal noted that treatment decisions in biochemically recurrent prostate cancer are often predicated on PSA kinetics alone. Therefore, ADT plus apalutamide could be considered for high-risk patients with a short PSA doubling time.

Disclosures: This research was supported by Alliance Foundation Trials, LLC, and Janssen Research & Development, LLC. Some of the study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original references for a full list of disclosures.

Reference

Aggarwal R, Heller G, Hillman D, et al. PRESTO: A phase 3, open-label study of androgen annihilation in patients (pts) with high-risk biochemically relapsed prostate cancer (AFT-19). Presented at ESMO 2022; September 9-13, 2022. Abstract LBA63.

This article originally appeared on Cancer Therapy Advisor